Acp iv lp - direct investment history in Acelrx pharmaceuticals inc

Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 14713 shares remaining shares owned 0

Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 14713 underlying security title Common Stock

f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 54875 shares at $5.00 remaining shares owned 14713

Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 54875 underlying security title Common Stock

f13 these shares reflect the net exercise of the series c warrant pursuant to the terms fo the warrant into 14,713 shares of the issuer's series c preferred stock.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 69588 shares remaining shares owned 0

Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 69588 underlying security title Common Stock

f13 these shares reflect the net exercise of the series c warrant pursuant to the terms fo the warrant into 14,713 shares of the issuer's series c preferred stock.
f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 69588 shares remaining shares owned 0

Warrant To Purchase Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 69588 underlying security title Series C Preferred

f10 the exercise price is $3.9428 per share and immediately exercisable prior to and contingent upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f12 pursuant to its terms, warrant shall terminate at the closing of the issuer's intial public offering. holder has elected to net exercise the warrants contingent upon and effective immediately prior to the closing of the issuer's initial public offering of common stock.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc remaining shares owned 0

Convertible Promissory Notes Acelrx Pharmaceuticals Inc Acrx underlying security shares 279097 underlying security title Common Stock transactional total value $1097487.00

f5 notes and accrued interest in the aggregate of $1,116,388.59 converted automatically upon the closing of the issuer's initial public offering into shares of common stock at a conversion price of $4.00, which is 80% of the per share price of the common stock sold in the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 40865 shares remaining shares owned 69588

Warrant To Purchase Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 40865 underlying security title Series C Preferred

f10 the exercise price is $3.9428 per share and immediately exercisable prior to and contingent upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f8 pursuant to note and warrant transfer agreement dated february 16, 2011, acp iv, l.p. transferred (i)a convertible promissory note in the amount of $655,656.79 including accrued interest and (ii)an associated warrant to purchase preferred stock on the issuer, exercisable into 40,865 shares of series c preferred stock.
f11 pursuant to its terms, warrant would terminate at the closing of the issuer's intial public offering. in the event the issuer's public offering did not occur, the warrant would have terminated on september 14, 2017, unless earlier terminated in accordance with its terms, in a liquidation or change of control transaction.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc remaining shares owned 0 at $1097487.00

Convertible Promissory Notes Acelrx Pharmaceuticals Inc Acrx underlying security shares 163914 underlying security title Common Stock transactional total value $644556.00

f9 principal amount plus interest converts automatically upon the closing of the issuer's initial public offering into shares of common stock at a conversion price of $4.00, which is 80% of the per share price of the common stock sold in the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f8 pursuant to note and warrant transfer agreement dated february 16, 2011, acp iv, l.p. transferred (i)a convertible promissory note in the amount of $655,656.79 including accrued interest and (ii)an associated warrant to purchase preferred stock on the issuer, exercisable into 40,865 shares of series c preferred stock.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 810129 shares remaining shares owned 0

Series C Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 810129 underlying security title Common Stock

f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 218750 shares remaining shares owned 0

Series B Convertible Preferred Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 328064 underlying security title Common Stock

f3 the shares reflect the automatic conversion of 218,750 shares of series b preferred stock for 328,064 shares of common stock immediately prior to the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc sold 500000 shares remaining shares owned 0

Series A Convertible Prefered Stock Acelrx Pharmaceuticals Inc Acrx underlying security shares 682904 underlying security title Common Stock

f1 the shares reflect the automatic conversion of 500,000 shares of the issuer's series a preferred stock for 682,904 shares of the issuer's common stock immediately prior to the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
f6 immediately convertible into shares of the issuer's common stock.
f7 these shares have no expiration date.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 680000 shares at $5.00 remaining shares owned 2794907

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: P Open market or private purchase of securities

f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 14713 shares remaining shares owned 2114897

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: C Conversion of derivative security (usually options)

f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 279097 shares remaining shares owned 2100194

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: C Conversion of derivative security (usually options)

f5 notes and accrued interest in the aggregate of $1,116,388.59 converted automatically upon the closing of the issuer's initial public offering into shares of common stock at a conversion price of $4.00, which is 80% of the per share price of the common stock sold in the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 810129 shares remaining shares owned 1821097

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: C Conversion of derivative security (usually options)

f4 the shares reflect the automatic conversion of shares of the issuer's series c preferred stock into common stock on a one-to-one basis upon the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 328064 shares remaining shares owned 1010968

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: C Conversion of derivative security (usually options)

f3 the shares reflect the automatic conversion of 218,750 shares of series b preferred stock for 328,064 shares of common stock immediately prior to the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.


Filed on 2011-02-18 by Acelrx Pharmaceuticals Inc SEC CIK 1427925 Form 4

Accession 0001209191-11-011322.txt Sec File: edgar/data/1427925/0001209191-11-011322-index.htm

2011-02-16 Acp Iv Lp (CIK 1282908) through Direct

Invested in Acelrx Pharmaceuticals Inc bought 682904 shares remaining shares owned 682904

Common Stock Acelrx Pharmaceuticals Inc Acrx Transaction code: C Conversion of derivative security (usually options)

f1 the shares reflect the automatic conversion of 500,000 shares of the issuer's series a preferred stock for 682,904 shares of the issuer's common stock immediately prior to the closing of the issuer's initial public offering.
f2 acmp iv, llc ("acmpiv") is the general partner of acp iv, l.p. ("acpiv") jean deleage, daniel janney, david mack, and guy nohra are directors of acmpiv and may be deemed to share voting and dispositive power with respect to all securities of the issuer held by acpiv. guy nohra is also a director of the issuer. mr. deleage, mr. janney, mr. mack, and mr. nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.